Rotigotine, a nonergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMA and FDA marketing authorization for the treatment of adult patients with early or advanced Parkinson's disease or with moderate-to-severe restless legs syndrome (RLS). This review comprises an overview of the pharmacokinetics, the pharmacodynamics and the clinical efficacy and safety of the rotigotine transdermal patch for RLS. Its source material was identified by a PubMed search for the terms 'rotigotine' and 'RLS'. The rotigotine transdermal patch demonstrates clinical efficacy alongside a good tolerability profile. Application site reactions were the most frequent adverse events, and they were considered mild to moderate in the majority of cases. In summary, the rotigotine transdermal patch offers a safe and efficacious alternative for the treatment of RLS. Further studies should focus on the possibility that continuous dopamine stimulation by means of transdermal patches might have an influence on RLS augmentation rates.
Introduction
The restless legs syndrome (RLS), also known as Ekbom's syndrome or anxietas tibiarum, is a sensorimotor disorder characterized by a nearly irresistible urge to move the lower limbs (less frequently the upper limbs), usually associated with a discomfort sensation deep inside the limbs. minergic neurons arrive at the dorsal horn and then project to the motor neuronal site. Downregulation of the inhibition at the spinal level due to dysfunction of A11 dopaminergic neurons might be responsible for impaired somatosensory integration and for PLM pattern generation [16] . An altered motor cortical excitability and defective cortical integration of sensory and motor information, which can be reverted by dopaminergic treatment, have also been proposed to explain the urge to move which characterizes the RLS [17] [18] [19] .
In 2007, the rotigotine transdermal patch has been approved by the regulatory authorities in Europe for use in all stages of Parkinson's disease (PD), at doses of 2-8 mg/day for early PD and of 4-16 mg/day for advanced PD patients. The marketing authorization for this indication originally granted by the FDA was suspended in 2008 due to crystal formation in the patches, but was granted again in 2012. At doses of 1, 2 and 3 mg/24 h, the rotigotine transdermal patch also received EMA marketing authorization for the treatment of adult patients with moderateto-severe RLS in August 2008, and FDA authorization in 2012. This review will focus on the rotigotine transdermal patch. Other options for the treatment of RLS will also be briefly reviewed, and the place which rotigotine patch treatment has among them will be highlighted.
Pharmacodynamics and Pharmacokinetics of Rotigotine
The pharmacodynamics and pharmacokinetics of rotigotine have been extensively reviewed elsewhere [52] . As there is no animal model of RLS, there are no preclinical data about the effect of rotigotine on this disease, although preliminary results about the pharmacokinetics of rotigotine in RLS have recently been published [20] . A total of 1,995 blood samples were taken from 284 patients included in a rotigotine clinical trial [21] to quantify rotigotine plasma concentrations. The mean 24-hour rotigotine plasma concentrations showed a linear dose relationship and remained mainly unchanged between the first and fifth year of treatment.
Clinical Efficacy of Rotigotine
A summary of the characteristics of published studies on rotigotine are provided in table 1 . The efficacy and safety of rotigotine were initially investigated in a small sample of patients with moderate-to-severe RLS [22] . Three fixed doses of rotigotine (1.125, 2.25 and 4.5 mg) and placebo were applied by patches in a double-blind, randomized, parallel-group, multicenter, 1-week proof-of-concept study. The primary efficacy measure was the total score on the International Restless Legs Syndrome Scale (IRLS). Additionally, the RLS-6 scales, the Clinical Global Impression (CGI) scale and a sleep diary were used. Sixty-three patients were randomly assigned to the four groups. In the placebo group, a marked change of 8 points from baseline was noted; however, the improvement in the severity of RLS symptoms was much more pronounced, i.e. by >10 points, in all rotigotine groups. In the highest-dose group (4.5 mg/day of rotigotine), the improvement was almost twice as high (15.7 points) as in the placebo group (p = 0.0095). According to the RLS-6 scales, daytime symptoms significantly improved with all rotigotine doses. The CGI items supported the favorable efficacy of the 4.5-mg dose.
The efficacy and safety of the rotigotine transdermal patch were further tested in a double-blind, randomized, parallel-group, multicenter, 6-week dose-finding trial [23] . The primary efficacy measure was the total score on the IRLS. In addition, the RLS-6 scales and the CGI scale were administered. A total of 341 patients were randomized to receive placebo or 0. Of the 310 patients who finished the abovementioned controlled trial, 295 were entered in an open-label uncontrolled extension trial [21] . At the end of the first year of follow-up, the mean daily dose was 2.8 ± 1.2 mg/24 h, with 4 mg/24 h being the most frequently applied dose (40.6%). The IRLS total score improved by -17.4 ± 9.9 points between baseline and the end of year 1 (p < 0.001). Follow-up information at the end of year 2 was available for 190 out of the 295 patients who finished the double-blind controlled trial [24] . The mean daily rotigotine dose after 2 years was 2.93 ± 1.14 mg/24 h, with a 2.9% dose increase from year 1. The IRLS total score improved by -17.2 ± 9.2 from baseline to year 2.
Two other large, randomized, double-blind, placebo-controlled trials have also been published [25, 26] . In the first one, Trenkwalder et al. [26] treated 458 patients with placebo or 1, 2 or 3 mg/day of rotigotine for 6 months. In the other one, Hening et al. [25] did the same with 505 patients, except that a 0.5 mg/day arm was included. Trenkwalder et al. [26] observed that the mean change in the IRLS sum score from baseline at the end of the maintenance phase was -13.7 ± 0.9 in the 1-mg group, -16.2 ± 0.9 in the 2-mg group and -16.8 ± 0.9 in the 3-mg group versus -8.6 ± 0.9 in the placebo group (p < 0.0001 for treatment difference vs. placebo for each dose). The mean change in CGI item 1 score from baseline at the end of the maintenance phase was -2.09 ± 0.14 in the 1-mg group, -2.41 ± 0.14 in the 2-mg group and -2.55 ± 0.14 in the 3-mg group versus -1.34 ± 0.14 in the placebo group (p < 0.0001 for treatment difference vs. placebo with each dose). The results from the trial by Hening et al. [25] were essentially similar, except that no difference between placebo and the doses of 0.5 or 1 mg/day were found. Trenkwalder et al. [26] also observed that the mean changes in RLS-QoL sum score from baseline at the end of the maintenance phase were -13.1 ± 14.8 in the 1-mg group, -15.7 ± 12.8 in the 2-mg group and -17.5 ± 4.2 in the 3-mg group versus -7.3 ± 13.5 in the placebo group, thus suggesting a dose response in the improvement of the quality-of-life score after rotigotine. Rotigotine was also shown to significantly improve daytime functioning, daytime symptoms, mood disturbances and depressive symptoms, and to reduce impairment of daily activities due to pain in post hoc analyses [27] [28] [29] .
The dose-related efficacy across the three abovementioned pivotal, double-blind, randomized studies employing the IRLS as their primary efficacy criterion and lasting ≥ 6 weeks [23, 25, 26] is shown in figure 1 . A simple look at the figure suggests that the maximal efficacy is attained with 3 mg/day of rotigotine.
Finally, a randomized, placebo-controlled polysomnographic study was conducted on subjects with moderate-to-severe RLS and PLM to assess the efficacy of rotigotine in ameliorating the latter [30] . The mean PLM index (PLMI; PLM per hour of time in bed) decreased more with rotigotine (from 50.9 to 8.1/h) than with placebo (from 37.4 to 27.1/h; adjusted treatment ratio = 4.25; 95% CI: 2.48-7.28; p < 0.0001). At the end of the maintenance phase, 39% of the rotigotine subjects had PLMI levels of <5/h, and 26% showed no RLS symptoms (IRLS score 0), whereas no placebo subject met these criteria.
Safety and Tolerability
The safety data from the pivotal double-blind, placebo-controlled, randomized studies are shown in table 2 [23, 25, 26] . Overall, no major safety concerns were found in both doubleblind and long-term open-label studies. The most frequent adverse events were application site reactions, nausea/vomiting or headache. Generally, application site reactions were cited as the most common adverse events in the rotigotine clinical studies [23, 25, 26] . Between 25 and 52% of the patients on the highest dose of rotigotine had application site reactions (including erythema, pruritus and dermatitis), in comparison with 2-5% of the patients receiving placebo treatment. However, the majority of these events were rated as mild to moderate and appeared to be dose related only for the moderate-to-severe site reactions. The occurrence of some dopaminergic adverse events such as nausea and vomiting appeared dose related, while other adverse events, including dizziness, showed no differences in occurrence between rotigotine-and placebo-treated patients [23, 25, 26] . Long-term safety was explored in the aforementioned open-label study [21] , where 79% of the patients experienced adverse events after 12 months of treatment with rotigotine. Skin reactions at the application sites of the patches were reported in 40% of the patients. Some serious dopaminergic adverse events were noted. Three patients reported sleep attacks or sudden onset of sleep (under 2 and 3 mg/24 h of rotigotine), and 1 patient reported hallucinations (under 2 mg/24 h of rotigotine). During the second year of follow-up, 131 of 220 patients (59.6%) experienced adverse events [24] . Application site reactions occurred in 16.4% of the patients. There were 2 cases of somnolence, 5 of depression, 1 of insomnia and 2 of parasomnia, among others.
Occurrence of augmentation was assessed by a preliminary version of the Augmentation Severity Rating Scale in two large trials [25, 26] or by unsolicited reports by the patients and their documentation by the investigator in all the RLS studies [23, 25, 26] . In general, no signs of augmentation were noted. A retrospective reanalysis of the data by predefined board members employing criteria based on the IRLS showed a clinically relevant augmentation in 1.5 or 0.5% of rotigotine-or placebo-treated patients in a 6-month double-blind study [25] , and in 2.9% over 12 months in an open-label follow-up study [21] . Five-year follow-up data [32] , or who had discontinued the study because of loss of efficacy, were further examined by an international expert panel for definite confirmation and clinical evaluation. The MPI criteria for augmentation were met by 145 patients (49.2%); the diagnosis was confirmed in 69 patients (24.3%) and clinical significance in 39 patients (13.2%). Discontinuation due to augmentation occurred in 12 cases (4.1%). Of all the patients with clinically significant augmentation, 61% were on 4 mg/day of rotigotine, which is a nonapproved dose. Interestingly, in 61% of the patients, the first episode took place after 1 year of treatment. While the frequency of augmentation decreased over time, new episodes were more frequently clinically significant.
Comparison of Rotigotine's Safety Profiles for PD and RLS
It is interesting to further compare the safety profiles of rotigotine between PD and RLS studies. Frequencies of application site reactions or of some of the most frequent dopaminergic adverse drug reactions were extracted, if available, from rotigotine PD [33] [34] [35] [36] [37] or RLS studies [25, 26] lasting ≥ 6 months. This analysis was complicated by differential adverse event reporting in the trials reviewed. The results are shown in table 3 . In the first place, the frequencies of the recorded adverse events were compared between the placebo groups of the PD and RLS studies. Application site reactions, dizziness, nausea/vomiting and somnolence were less frequently observed with placebo in the RLS studies compared with the same group in the PD studies (all p < 0.01). The differences in the frequencies of dopaminergic adverse drug reactions between the two groups could possibly be explained by differences in the consumption of other antiparkinsonian medications. Conversely, there is no clear explanation for the difference in the frequency of application site reactions. These results indicate that the reason why PD patients on placebo report adverse events more frequently than do RLS patients may not be related to medications or the disease itself but to other unknown factors. [37] (2007). R = Rotigotine. ** p < 0.01 vs. placebo groups in PD studies (χ 2 test). 1 The frequency of adverse events in the study by Poewe et al. [37] was lower than in the other trials.
A further look at table 3 reveals that dopaminergic adverse events, but not application site reactions, are more frequent in rotigotine-treated PD patients than in rotigotine-treated RLS patients. In general, the PD studies used higher rotigotine doses than the RLS studies, which could explain the aforementioned differences. Nonetheless, it should also be kept in mind that PD patients in the main may be more prone to report adverse events than RLS patients.
The Place of Rotigotine in the Treatment of RLS
Other pharmacological options for RLS treatment have been investigated in several clinical trials, many of which were randomized and controlled ( table 4 ). The parameter most frequently evaluated was the IRLS score. Dopaminergic agonists are the first-line agents for the treatment of RLS symptoms [14] . Several randomized controlled studies showed significant changes if patients were treated with 0.25-6 mg/day of ropinirole for 4-12 weeks R = Randomized; DB = double-blind; C = controlled; MC = multicenter; CO = crossover; VAS = visual analog scale.
( table 4 ) [38] [39] [40] . The efficacy of ergot agonists such as cabergoline (2 mg) was demonstrated in studies employing levodopa as the active comparator [41] . Treatment with 0.125-0.75 mg/day of pramipexole was also explored, with positive results [42, 43] . In general, the safety profiles were good, but these drugs can lead to severe adverse events such as diurnal somnolence, impulse control disorders and augmentation in some patients [44] . Cabergoline is a second-line therapy as ergot dopamine agonists have been shown to increase the risk of fibrotic adverse events. The efficacy of rotigotine ( fig. 1 ) appears to be comparable to that of the other agonists for this indication.
In an attempt to find equally effective drugs but without the aforementioned tolerability issues, other drug treatment options have been explored, but there are no head-to-head comparisons of different active agents. The dose-related efficacy of pregabalin (50-450 mg/ day) was demonstrated in randomized, controlled studies [45, 46] . Gabapentin (>1,300 mg/ day) was efficacious as compared with placebo in a randomized, double-blind crossover study [47] . Gabapentin effects appear to be similar to those of dopamine agonists. Results from a small head-to-head pragmatic study comparing gabapentin ( ≤ 1,200 mg) with ropinirole ( ≤ 1.5 mg) showed that these treatments may demonstrate a comparable efficacy ( table 4 ) [48] . The efficacy of iron supplements was tested in primary or iron-deficient RLS patients ( table 4 ) . Improvements were observed in iron-deficient patients [49] , but not in primary RLS patients [47] .
Conclusions
Rotigotine is a D 1 -D 5 receptor agonist, with the highest affinity for the D 3 receptor. The rotigotine transdermal patch has demonstrated its clinical efficacy for the treatment of RLS. The tolerability of the rotigotine patch appears to be well within the range of what is known and expected from other dopamine agonists, except for application site reactions, which appear to be only mild to moderate in the majority of cases. Nonetheless, such reactions could limit the practicability of this therapy for a number of patients. Interestingly, application site reactions affect PD and RLS patients with a similar frequency, which appears not to be the case for dopaminergic adverse events such as nausea/vomiting, somnolence or dizziness ( table 3 ) . Moreover, impulse control disorders have been correlated with rotigotine administration in PD patients but not in RLS patients. This might be related to the dose. Nonetheless, as shown by the comparison of placebo-treated PD with placebo-treated RLS patients ( table 3 ) , PD patients may be more prone to disclose their adverse events independently of the drug and dose administered.
Rotigotine appears to provide relief to RLS patients ( fig. 1 ) as compared with other treatments ( table 4 ) . Therefore, rotigotine can be considered a first-line treatment for RLS. In addition, the transdermal application of rotigotine may offer some advantages beyond those of many of the alternative oral pharmacological options, such as the provision of stable plasmatic levels during 24 h. Such an advantage may be of special interest to RLS patients suffering from both nocturnal and diurnal symptoms as it could contribute to reducing augmentation. A recent study suggested that long-acting dopamine agonists, preferably with D 2 and D 3 receptor affinity, may reduce the augmentation risk [50] . Rotigotine might be a good option for offering symptomatic relief from RLS with a low risk of augmentation. Nonetheless, as this issue has not been sufficiently evaluated in long-term trials, any conclusion is speculative. As a final advantage, the once-daily transdermal patch formulation may favor compliance by providing a convenient means of administration.
